For adults who have moved away from cigarettes, tobacco policy can feel far removed from the experiences that helped them stop smoking. An appointment to the FDA’s tobacco advisory committee offers a reason to pay attention: a tobacco harm reduction advocate now has a voting seat representing the general public. 

On October 14, 2026, the FDA announced four new voting members of its Tobacco Products Scientific Advisory Committee, commonly known as TPSAC. Among them is Kim “Skip” Murray, whose advocacy has focused on listening to people who smoke and those who have switched to alternative nicotine products. 

The agency is also accepting nominations for two additional voting positions. For adult consumers, the announcement raises an important question: how might broader perspectives inform the scientific discussions that help shape tobacco regulation? 

 

Why Skip Murray’s Appointment Matters 

Murray is a longtime tobacco harm reduction advocate and former vape shop owner who smoked for nearly five decades before switching to vaping. Her background brings personal experience with smoking and an understanding of the adults who seek alternatives. 

That perspective matters because moving away from cigarettes is deeply personal. People arrive with different smoking histories, previous quit attempts, circumstances, and preferences. A discussion about tobacco policy should make room for those differences. 

Scientific evidence remains essential. Consumer experience can help identify the practical questions that evidence needs to address: What keeps someone smoking? What makes an alternative acceptable enough to use consistently? What barriers stand between wanting to stop and actually leaving cigarettes behind? 

Murray’s appointment creates an opportunity for those questions to receive attention within the committee’s deliberations. 

 

A Voting Representative for the General Public 

The FDA specifically identifies Murray as the committee’s representative of the general public. She joins Holger Behrsing, Ph.D.; Margaret Nolan, M.D.; and Andrew A. Strasser, Ph.D., as newly announced voting members. 

The agency describes their combined expertise as spanning preventive medicine, chronic disease, cessation, harm reduction, toxicology, cell biology, and health communication. 

Separately, Eric Ray Walker, Ph.D., was selected as an alternate, non-voting representative of tobacco growers’ interests. Murray’s appointment is to a voting public seat, distinct from those industry positions. 

For consumers following this announcement, that distinction helps explain her role. She will participate in scientific deliberations as the designated public representative, with a vote on questions brought before the panel. 

 

What Does TPSAC Actually Do? 

The Tobacco Products Scientific Advisory Committee advises the FDA commissioner on tobacco-related scientific and technical issues. Its work includes evaluating questions about product safety, dependence, and health effects. 

Its responsibilities also extend to reviewing applications for modified-risk tobacco products. These applications concern whether a manufacturer may market a product with particular claims about reduced risk or reduced exposure. 

That makes the committee relevant to discussions about how consumers understand differences between tobacco products—and how proposed claims might affect their decisions. 

For example, when announcing a TPSAC meeting concerning ZYN modified-risk applications, the FDA explained that the discussion would examine relative health risks, consumer understanding of the proposed claim, and potential effects on public health. 

These are consequential questions. Communicating risk requires accuracy, but it also requires understanding the people receiving the information. 

 

What This Means for Adult Consumers 

From a tobacco harm reduction perspective, Murray’s appointment is an encouraging development. 

Adult consumers deserve meaningful consideration in discussions about products they use and policies that affect their choices. Someone who has experienced the difficulty of leaving cigarettes behind can bring useful questions to a scientific discussion, particularly when the conversation turns to behavior, communication, and barriers to switching. 

There is also a practical reason to welcome a range of expertise. Laboratory research, clinical experience, behavioral science, and public perspectives address different parts of the same problem. Thoughtful deliberation benefits from examining how those pieces fit together. 

The appointment itself does not establish how Murray or the other members will vote on any particular issue. Their contributions will become clearer through the evidence they examine, the questions they ask, and the recommendations they help develop. 

 

An Advisory Role With Clear Limits 

TPSAC provides advice and recommendations. FDA advisory committee recommendations are nonbinding; final regulatory decisions remain with the agency. The committee does not independently authorize products or establish FDA policy. 

For that reason, these appointments should not be read as an announcement of new vape authorizations, a change in enforcement, or a promise about future regulatory outcomes. 

Their significance lies in who will participate in the scientific conversation. For people who want adult smokers’ experiences taken seriously, that is worth watching. 

 

FDA Is Seeking Two More Voting Members 

The nomination process also offers qualified professionals an opportunity to contribute. The FDA is seeking candidates in relevant medical, scientific, and engineering fields. Individuals may nominate themselves or be nominated by others. 

December 14, 2026, is the deadline for first consideration. Selected members may serve terms of up to four years. Submission options and instructions are available through the FDA announcement. 

 

A Reason to Pay Attention 

For MiPod’s adult audience, the most meaningful part of this announcement is the opportunity for lived experience to inform discussions alongside scientific expertise. 

The next test will be how that opportunity translates into the committee’s work. Tobacco policy should ask rigorous questions about risk, dependence, and population effects while keeping sight of the adults who are still smoking—and what might help them move away from cigarettes.